Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States
| Autor: | Devarshi Bhattacharyya, Taha Khan, Harsheen Sethi, Wambui Gathirua-Mwangi, Manuel Afable |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Colorectal cancer Leucovorin Cetuximab medicine.disease_cause Proto-Oncogene Proteins p21(ras) FOLFOX Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Panitumumab Humans neoplasms business.industry Health Policy Antibodies Monoclonal medicine.disease digestive system diseases United States Irinotecan Fluorouracil FOLFIRI Costs and Cost Analysis KRAS business Colorectal Neoplasms medicine.drug |
| Zdroj: | Journal of medical economics. 24(1) |
| ISSN: | 1941-837X |
| Popis: | To compare the cost of biweekly regimens of first-line (1L) treatments of cetuximab-folinic acid, fluorouracil, and irinotecan (FOLFIRI)Cost-minimization analysis (CMA) was performed to estimate per-patient cost differences of cetuximab-FOLFIRIFor the base case, total treatment costs were $167,853 for cetuximab-FOLFIRI and $168,254 for panitumumab-FOLFOX; cost savings per patient receiving cetuximab-FOLFIRI was $400. Cost savings in alternate scenarios (men, $15,138; women, $15,004) resulted from lower drug acquisition costs for cetuximab (men, $14,833; women $14,854) and administration cost ($440)With no head-to-head clinical trial data in the 1L setting, assumptions of similarity in efficacy and safety of cetuximabBiweekly cetuximab-FOLFIRI offers cost savings compared with panitumumab-FOLFOX for 1L therapy of patients with KRAS WT mCRC in the United States. These cost differences were observed for the overall population and across different BSA and weights for men and women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|